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The feasibility of sequential carboplatin followed by docetaxel-based therapy for untreated ovarian cancer was determined. Patients
received four q3w cycles of carboplatin AUC 7, then four q3w cycles of either docetaxel 100mgm
 2 (day 1) (arm A); docetaxel
75mgm
 2 (day 8) and gemcitabine 1250mgm
 2 (days 1,8) (arm B) or docetaxel 25mgm
 2 and gemcitabine 800mgm
 2 (both
given weekly (days 1,8,15)) (arm C). A total of 44 patients were randomised to each treatment arm. None of the arms demonstrated
an eight cycle completion rate (70.5/72.7/45.5% in arms A/B/C, respectively), which was statistically greater than 60% (P¼0.102,
P¼0.056, P¼0.982) which was our formal feasibility criteria, although only the completion rate in arm C was clearly worse than this
level. The overall response rate (ORR) after carboplatin was 65.7% in 70 evaluable patients. In evaluable patients, ORRs after
docetaxel-based cycles were: arm A 84.0% (21 out of 25); arm B 77.3% (17 out of 22); arm C 69.6% (16 out of 23). At follow-up
(median 30 months), median progression-free survival times were: arm A 15.5 months (95% CI: 10.5–20.6); arm B 18.1 months (95%
CI: 15.9–20.3); arm C, 13.7 months (95% CI: 12.8–14.6). Neutropenia was the predominant grade 3–4 haematological toxicity:
77.8/85.7/54.4% in arms A/B/C, respectively. Dyspnoea was markedly increased in both gemcitabine-containing arms (P¼0.001) but
was worse in arm C. Although just failing to rule out eight cycle completion rates less than 60%, within the statistical limitations of
these small cohorts, the overall results for arms A and B are encouraging. Larger phase III studies are required to test these
combinations.
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Primary cytoreductive surgery plus chemotherapy is the standard
treatment for patients with advanced epithelial ovarian cancer,
with paclitaxel–carboplatin now considered the treatment of
choice for first-line chemotherapy (Kaye, 2000). However, despite
a modest improvement in survival in recent years, the median
5-year survival for advanced-stage disease remains poor at 31%
(American Cancer Society, 2004).
Peripheral neuropathy is a common adverse event associated
with paclitaxel-based therapy (Guastalla and Dieras, 2003) and can
lead to early treatment discontinuation. Docetaxel is a second-
generation taxane that has pharmacological and pharmacokinetic
advantages over paclitaxel (Gligorov and Lotz, 2004) and a
substantially different toxicity profile to paclitaxel when combined
with carboplatin (Hsu et al, 2004). Like paclitaxel, docetaxel has
significant activity in ovarian cancer (Ma ¨enpa ¨a ¨, 2003) and recently
the first Scottish Randomised Trial in Ovarian Cancer (SCOTROC
1) established that docetaxel–carboplatin provides similar survi-
val, less neurotoxicity and greater improvement in some quality of
life (QoL) parameters compared with paclitaxel–carboplatin
(Vasey et al, 2004).
The addition of a third cytotoxic agent to a platinum–taxane
doublet may potentially improve outcomes in ovarian cancer. High
response rates have been reported when gemcitabine is added to a
paclitaxel–platinum combination for advanced ovarian cancer
(Hansen, 2002), albeit at the expense of significant haematological
toxicity (Berkenblit et al, 2003; Barlow et al, 2004). Likewise,
addition of pegylated liposomal doxorubicin (PLD) to frontline
carboplatin–paclitaxel as a concurrent triplet necessitates sig-
nificant PLD dose reduction (Bookman, 2003). Strategies that may
potentially reduce such toxicities from triple-agent regimens
include sequential scheduling or the use of alternating or
sequential doublets. All these are currently being evaluated as an
alternative to paclitaxel–carboplatin in the recently completed Revised 11 November 2005; accepted 18 November 2005
*Correspondence: Dr PA Vasey; E-mail: Paul_Vasey@health.qld.gov.au
9Present address: University of Queensland, Division of Medicine,
Brisbane, Australia, Q4029
P Vasey, R Atkinson, R Osborne, D Parkin, S Paul, R Coleman, J Paul, EA
Lewsley, S Kaye, R Gordon, for the Scottish Gynaecological Cancer Trials
Group (2003). Carboplatin (Cb) followed sequentially by docetaxel (D)
7gemcitabine (G) in ovarian, peritoneal and fallopian tube cancers:
results of SCOTROC 2A. Proc Am Soc Clin Oncol 22: 449 (abstract
1804).
British Journal of Cancer (2006) 94, 62–68
& 2006 Cancer Research UK All rights reserved 0007– 0920/06 $30.00
www.bjcancer.com
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sfive-arm trial conducted by the Gynaecologic Oncology Group
(GOG) and the International Collaborative Ovarian Neoplasm
(ICON) group (GOG-182/ICON5). Survival data are not expected
to be reported before 2006.
A sequential-type approach may not only reduce toxicity but
might also help to overcome any antagonism which may exist
between agents – one possible reason for the failure of paclitaxel–
carboplatin to improve survival over carboplatin alone in the
ICON3 trial (International Collaborative Ovarian Neoplasm Group,
2002). Further support for a sequential approach is based on
studies which show that ovarian cancer cells with abrogated p53
gene function are sensitised to taxanes (Cassinelli et al, 2001), and
that ovarian tumours with mutated p53 are more responsive to
taxanes and less responsive to platinum agents than wild-type p53-
expressing tumours (Lavarino et al, 2000; Reles et al, 2001). Thus,
initial platinum treatment might eradicate one tumour population
of wild-type p53 cells, leaving a population of predominantly
mutant p53 cells amenable to treatment with taxanes. In the
clinical setting, results from trial GOG-132 suggest that platinum
therapy followed – prior to clinical progression – by paclitaxel
does not result in loss of efficacy when compared with concurrent
administration (Muggia et al, 2000). This randomised study was
designed to assess the feasibility of sequentially scheduling single-
agent carboplatin followed by docetaxel alone or a docetaxel–
gemcitabine doublet as first-line therapy for ovarian cancer.
PATIENTS AND METHODS
Patients
Female patients aged X18 years with histologically confirmed
epithelial ovarian carcinoma, fallopian tube cancer or ovarian-type
primary peritoneal cancer were eligible for the study. Additional
inclusion criteria were: International Federation of Gynecologic
Oncology (FIGO) stages Ic–IV; Eastern Cooperative Oncology
Group performance status p2; no prior chemotherapy or radio-
therapy; adequate bone marrow, hepatic and renal function.
Exclusion criteria included: mixed mesodermal tumours; tumours
considered borderline or ‘possibly malignant’; concurrent malig-
nancy or malignancy within the previous 5 years (except curatively
treated uterine cervical carcinoma in situ or basal cell skin
carcinoma); history of prior serious allergic reactions; pregnancy
or lactation; symptomatic peripheral neuropathy Xgrade 2.
The study had central International Review Board approval and
all patients gave written informed consent. Randomisation took
place within 8 weeks of initial surgery (laparotomy/biopsy) and
patients were allocated to treatment using a minimising algorithm
with the following factors: extent of residual disease; centre; FIGO
stage; performance status; tumour grade; pretreatment CA-125;
presence or absence of primary peritoneal or fallopian tube cancer;
interval debulking intention.
Treatment
Eight cycles (24 weeks) of chemotherapy were planned at 3-weekly
intervals. After randomisation, all eligible patients received four
cycles of carboplatin AUC (area under the curve) 7 (1-h infusion)
on day 1 of each cycle. The dose of carboplatin was derived via
the Calvert formula (mg¼(glomerular filtration rateþ25) 7)
(Calvert et al, 1989) and by using
51Cr EDTA (edetic acid)
measurement of glomerular filtration rate (Chantler et al, 1969).
This dose remained fixed for all cycles unless toxicity mandated
dose reduction.
Patients then received either four cycles of docetaxel 100mgm
 2
(1-h infusion) on day 1 (arm A); four cycles of docetaxel
75mgm
 2 (1-h infusion) on day 8 plus gemcitabine 1250mgm
 2
(30-min infusion) on days 1 and 8 (arm B); four cycles of docetaxel
25mgm
 2 plus gemcitabine 800mgm
 2, both given as 30-min
infusions on days 1, 8 and 15 (arm C). Gemcitabine was always
administered after docetaxel.
Premedication for docetaxel comprised dexamethasone 8mg
twice daily for 3 days starting the day before docetaxel
administration; oral antiemetics included granisetron 1mg pre-
chemotherapy and domperidone 20mg up to four times daily if
required.
Cycles were repeated in the absence of progressive disease or
prohibitive toxicity. Interval debulking surgery was permitted after
finishing carboplatin treatment and before starting docetaxel-
based therapy (provided chemotherapy was restarted within 3
weeks).
Dose/schedule modifications
Treatment was delayed for up to 2 weeks if the neutrophil count
was o1.5 10
9l
 1 or the platelet count was o100 10
9l
 1.
Prophylactic antibiotics were recommended for subsequent cycles
following grade 4 febrile neutropenia. This was treated by standard
protocols involving hospital admission, intravenous antibiotics
and (if required) the use of granulocyte-colony-stimulating factors.
The following dose reductions were indicated at first occurrence
of neutrophils o1.5 10
9l
 1 or platelets o100 10
9l
 1 lasting
41 week but o2 weeks, neutropenic fever, or complicated grade 4
thrombocytopenia: carboplatin reduction to AUC 6 (all arms), and
a docetaxel reduction to 75mgm
 2 in arm A or a 25% reduction
for both gemcitabine and docetaxel in arms B and C. At the second
occurrence of these haematological toxicities, carboplatin was
reduced to AUC 5, docetaxel reduced to 60mgm
 2 (arm A), and
both drugs reduced by a further 25% (arms B/C). For grade 3–4
nonhaematological toxicity during docetaxel-based cycles, treat-
ment was delayed until toxicity reversed to pgrade 1; the doses on
subsequent cycles were then reduced by 25%. Treatment delay for
p2 weeks was allowed for mucositis grade X3, painful or
troublesome mucositis grade 2 and skin toxicity grade X2;
subsequent doses were reduced by 25%. In an attempt to improve
on the initially poor dose intensity observed in arm C, the protocol
was amended in June 2001 to lower the threshold for dose
reductions to a neutrophil count of o1.0 10
9l
 1 or a platelet
count of o75 10
9l
 1, with delays for complicated thrombo-
cytopenia mandated until platelets were X75 10
9l
 1.
For significant hypersensitivity reactions to docetaxel, the
infusion was stopped, symptoms were treated and patients
rechallenged within 3h without further premedication (if appro-
priate). Milder reactions were managed by slowing the infusion
rate, observation until recovery and then reinfusion at the initial
rate.
Clinical assessments
Before study entry, patients underwent a physical examination,
abdomino–pelvic computed tomography scan, electrocardiogram,
chest X-ray, CA-125, full biochemical profile, full blood count and
glomerular filtration rate measurement. Blood counts and
biochemical profiles were taken at the start of each carboplatin
cycle and weekly during docetaxel-based treatment. CA-125 level
was measured at the start of each cycle. Efficacy was assessed using
modified Southwest Oncology Group Solid Tumour Response
Criteria and by CA-125 (Rustin et al, 1996). Quality of life was
evaluated before starting treatment and before each treatment
cycle using the European Organisation for Research and Treatment
of Cancer questionnaires QLQ-C30 and QLQ-OV28 (Cull et al,
2001). Toxicities were documented throughout chemotherapy
using the National Cancer Institute Expanded Common Toxicity
Criteria (NCI-CTC, Version 2.0). Neurotoxicity was assessed using
a structured neurological questionnaire and examination before
study entry and after four and eight cycles (Cassidy et al, 1998).
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sAll patients were followed up every 2 months until progressive
disease was documented. Neurological and QoL assessments were
continued every 4 months for up to 2 years.
Statistical considerations
The primary end point for this randomised feasibility study was
the percentage of patients completing eight cycles of chemotherapy
within each treatment arm. A completion rate of X80% was
deemed clearly acceptable, 60–80% was deemed a ‘grey area’ and
p60% was deemed clearly unacceptable. The study was designed
to test the null hypothesis that the completion rate was p60%
against the alternative that it was 460%. The one-sided
significance level was set at 5% and the power of the study when
the true completion rate was 80% was set at 90%; this required 44
patients to be recruited to each treatment arm. The study was not
powered to detect significant differences in efficacy between the
three arms; randomisation was utilised in order to ensure that
patients with similar characteristics received each of the three
options. However, it also permitted a preliminary analysis to be
made of the range of efficacy to be expected.
Protocol-defined secondary end points were: toxicities, QoL,
clinical response rates and CA-125 responses, and progression-free
and overall survival (in particular, at 8 months) (end of treatment).
Toxicities and changes in QoL during taxane-based therapy were
compared between arms using the Mann–Whitney U-test. Quality
of life end points were examined in two sets: global health status
and functional scales, and symptom scales (including fatigue,
nausea and vomiting, pain, abdominal/gastrointestinal symptoms,
peripheral neuropathy and hair loss). The statistical significance of
the QoL comparisons was assessed by controlling the false
discovery rate at 5% (Benjamini and Hochberg, 1995) within each
of these sets. Progression-free survival was measured from the date
of randomisation to progression or death from any cause
(whichever came first). Survival times were also measured from
the date of randomisation to death from any cause. Kaplan–Meier
methods were used to generate survival curves and estimate
survival rates.
RESULTS
Patients
Between September 2000 and January 2002, 132 patients were
recruited and randomised (44 to each treatment arm) from 11
centres in UK and four centres in Switzerland. The arms were well
balanced with respect to baseline demographic and disease
characteristics (Table 1).
Treatment and completion rate
A total of 31 (70.5%; 90% confidence interval (CI): 57.2–81.6%), 32
(72.7%; 90% CI: 59.6–83.4%) and 20 (45.5%; 90% CI: 32.5–58.9%)
patients completed the full eight cycles (24 weeks) of planned
Table 1 Patient baseline characteristics
Docetaxel alone (arm A)
(n¼44)
Docetaxel–gemcitabine (3-weekly)
(arm B) (n¼44)
Docetaxel–gemcitabine
(weekly) (arm C) (n¼44)
% Count % Count % Count
Residual bulk
None/micro 36.4 16 34.1 15 36.4 16
p2cm 29.5 13 27.3 12 29.5 13
42cm 34.1 15 38.6 17 34.1 15
FIGO stage
Ic 4.5 2 6.8 3 6.8 3
II 15.9 7 9.1 4 11.4 5
III 65.9 29 70.5 31 68.2 30
IV 13.6 6 13.6 6 13.6 6
Tumour grade
Well 9.1 4 2.3 1 4.5 2
Moderate 25.0 11 25.0 11 27.3 12
Poor 56.8 25 61.4 27 56.8 25
Unknown 9.1 4 11.4 5 11.4 5
ECOG PS
0 36.4 16 38.6 17 38.6 17
1 59.1 26 54.5 24 54.5 24
2 4.5 2 6.8 3 6.8 3
Intent to have debulking operation
No 81.8 36 84.1 37 81.8 36
Yes 18.2 8 15.9 7 18.2 8
Cancer type
Ovarian 90.9 40 90.9 40 90.9 40
Peritoneal 6.8 3 6.8 3 9.1 4
Fallopian 2.3 1 2.3 1 0.0 0
CA-1254ULN prior to chemotherapy
No 11.4 5 18.2 8 13.6 6
Yes 88.6 39 81.8 36 86.4 38
CA-125¼cancer antigen 125; ECOG PS¼Eastern Cooperative Oncology Group Performance Status; FIGO¼International Federation of Gynecologic Oncology; ULN¼upper
limit of normal.
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streatment in arms A, B and C, respectively (primary end point).
None of the arms demonstrated a completion rate that was
statistically greater than 60% (P¼0.102, P¼0.056, P¼0.982),
which was our formal feasibility criteria; the completion rate in
arm C is markedly less than this level.
The progress of patients through the trial is shown in Figure 1.
Overall, 121 (91.7%) patients completed their initial four cycles of
carboplatin treatment, where 362 out of 505 (71.7%) cycles were
delivered on time; 48 (36.4%) patients had no delays, while 41
(31.1%) experienced a delay of one cycle. In most cases (86 (65.2%)
patients), the planned dose of carboplatin was given and only 12
(9.1%) patients had two or more dose reductions, resulting in a
median dose intensity of 92%.
Of the patients who proceeded to docetaxel-based therapy, 31
out of 37 (83.8%) patients, 33 out of 42 (78.6%) patients and 20 out
of 35 (57.1%) patients completed four cycles of treatment in arms
A, B and C, respectively (Figure 1). In arm A, 17 (45.9%) patients
had no cycle delays, 16 (43.2%) patients had one cycle delay and
four (10.8%) patients had two cycle delays. In arm B, nine (21.4%)
patients had no cycle delays and 31 (73.8%) had one to four delays
either on day 1 or day 8 of treatment. In arm C, only two (5.7%)
patients received all cycles on time and 25 (71.4%) experienced one
to four delays.
Dose intensities during docetaxel/gemcitabine chemotherapy
were calculated over the period following these agents’ first cycle;
delays starting docetaxel/gemcitabine as a result of prior
carboplatin therapy are not included. The median dose intensities
were 99% (docetaxel in arm A), 84% (docetaxel in arm B), 86%
(gemcitabine in arm B) and 73% (for both gemcitabine and
doceaxel in arm C). The protocol amendment resulted in the dose
intensity in arm C increasing from 55 to 74% (gemcitabine) and 55
to 73% (docetaxel).
In total, 24 (64.9%) patients in arm A received the full dose at
each cycle and 12 (32.4%) patients had one dose reduction. Full
dose was given as planned to most patients in arm B, with 30
(71.4%) and 33 (78.6%) patients receiving full doses of docetaxel
and gemcitabine, respectively. In this treatment arm, nine (21.4%)
patients experienced one docetaxel dose reduction and four (9.5%)
Patients assessed as eligible
Randomised (n=132)
Did not proceed to Docetaxel-based tratment phase (n=18):
Progressive disease (n=3)
Haematological toxicity (n=6)
Bowel obstruction (n=2)
Patient decision (n=6)
Clinician error (n=1)
 (n=37) [Arm A]  Gemcitabine (n=42) [Arm B]  Gemcitabine (n=35) [Arm C]
 Withdrawals (n=10)   Withdrawals  (n=15) 
 Progressive disease
   (n=1) 
 Progressive disease
 (n=3) 
 Withdrawals (n=6)
 Progressive disease/no
 response (n=3)
 Nonhaematological
 toxicity (n=2)
 Completion rate (n=44)  Completion rate (n=44)  Completion rate (n=44)
 CA-125 response (n=34)  CA-125 response (n=32)  CA-125 response (n=30)
 Safety during taxane-based 
 chemotherapy (n=37)
 Safety during taxane-based 
 chemotherapy (n=35)
 Safety during taxane-based 
 chemotherapy (n=42)
 QoL during taxane-based 
 chemotherapy (n=31)
 QoL during taxane-based 
 chemotherapy (n=29)
 QoL during taxane-based 
 chemotherapy (n=33)
 Tumour response (n=25; all 
 evaluable)
 Tumour response (n=23;  
 n=21 evaluable)
 Tumour response (n=22;  
 n=20 evaluable)
 Primary end point analysis  Primary end point analysis  Primary end point analysis
 Secondary end point analysis  Secondary end point analysis  Secondary end point analysis
 Nonhaematological
 toxicity (n=4)
 toxicity (n=2)
 Nonhaematological
 toxicity (including one
death) (n=6)
 Haematological toxicity
    (n=1)
 Haematological 
 Haematological 
 toxicity (n=3)
Patient decision (n=3)
 Adverse event 
 (including one death)
 (n=3)
Option for interval debulking before
Docetaxel-based treatment phase
Docetaxel alone 100 mg m–2
(n=44 in each of three arms)
Carboplatin AUC 7
3-weekly × 4 cycles
3-weekly Docetaxel and Weekly Docetaxel and
Figure 1 Patient journey through trial.
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shad one gemcitabine dose reduction. Dose reductions were more
common in arm C, with only 17 (48.6%) patients having no dose
reductions and 14 (40.0%) patients having one dose reduction.
Response
Clinical response data were available for 70 patients with
measurable disease during the carboplatin phase of the study,
although seven became unevaluable for various nonclinical
reasons (e.g. wrong investigation performed). The overall response
rate after this phase was 65.7% (46 out of 70), including 14 (20.0%)
complete and 32 (45.7%) partial responses. A total of 12 (17.1%)
patients had stable disease and five (7.1%) patients had progressive
disease. Data on tumour responses at the end of docetaxel-based
treatment were available for 25, 22 and 23 patients with measurable
disease in arms A, B and C, respectively, although four patients
subsequently became unevaluable (Table 2). The overall response
rates after all planned chemotherapy were 84% (10 complete and
11 partial responses), 77.3% (10 complete and seven partial
responses) and 69.6% (seven complete and nine partial responses)
in arms A, B and C, respectively. Of 96 patients evaluable for CA-
125 response, 72 (75.0%) responded – most (68 out of 72) before
docetaxel-based therapy began. Overall, 62.5% (10 out of 16
patients) in arm A, 100.0% (11 out of 11) in arm B and 87.5% (14
out of 16) in arm C had disease which remained stable or improved
after the carboplatin phase with the addition of four cycles of
docetaxel-based therapy.
Survival
At the time of this analysis, 86 patients had progressed or died. A
total of 79% of surviving patients had a minimum follow-up of 2
years and the median follow-up was 30 months. The 8-month
progression-free survival rate was 77.3% (standard error (SE) 6%)
in arm A, 93.1% (SE 4%) in arm B and 76.9% (SE 6%) in arm C; the
corresponding median progression-free survival times are 15.5
(95% CI: 10.5–20.6), 18.1 (95% CI: 15.9–20.3) and 13.7 (95% CI:
12.8–14.6) months, respectively.
Toxicity
Table 3 shows the incidence of grade 3–4 haematological toxicity
and neutropenic complications occurring during docetaxel-based
therapy. Anaemia was more severe in the gemcitabine-containing
arms (P¼0.002), as was thrombocytopenia (Po0.001). Neutrope-
nia was more severe in the docetaxel-alone arm (P¼0.015). No
patients had complicated thrombocytopenia. Table 3 also shows
the incidence of grade 2–4 nonhaematological toxicity that
occurred during docetaxel-based therapy. Alopecia was markedly
less in arm C (P¼0.001). Dyspnoea was markedly increased in
both gemcitabine-containing arms (P¼0.001), but was worse with
the weekly regimen (arm C). Furthermore, arm C was associated
with pulmonary infiltrates in three patients and one death due to
pulmonary toxicity. There was one further on-study death due to
neutropenic sepsis, which also occurred in arm C.
Quality of life
Quality of life data were available for 31, 33 and 29 patients in arms
A, B and C, respectively. Median changes in selected QoL measures
during docetaxel-based treatment (average recorded during
docetaxel-based therapy minus the value at the end of carboplatin
treatment) were compared between the treatment arms. After
adjustment for multiple testing, the only statistically significant
difference was in nausea and vomiting, which was higher in arm C
(median change 5.6; range  17.0 to 50) compared to arms A (0;
 100 to 20) and B (0;  44 to 33).
DISCUSSION
Sequential chemotherapy may potentially maximise the impact of
each chemotherapeutic agent while avoiding overlapping toxicities
caused by concurrent administration. Following the results of
ICON-3 and GOG-132, this represents a logical next step in the
evolution of induction chemotherapy for ovarian cancer (Muggia,
2003). Our results suggest that sequential chemotherapy with four
cycles of carboplatin AUC 7 followed by a 3-weekly schedule of
docetaxel-based chemotherapy is feasible as first-line treatment for
patients with ovarian cancer. Carboplatin followed by weekly
docetaxel–gemcitabine (arm C) was not well tolerated, and dose
intensity was compromised as evidenced by more dose delays,
dose reductions and a high rate of discontinuations during the
docetaxel-based phase (43%). Furthermore, the weekly docetaxel–
gemcitabine arm clearly failed the minimum criterion for
feasibility (460% completion rate for eight cycles). Although the
lower end of the 90% CIs for completion rates in the docetaxel-
alone and 3-weekly docetaxel–gemcitabine arms was just below
60%, their observed completion rates are sufficiently high to make
them worthy of consideration for further clinical testing.
Comparisons with toxicity seen in other trials and schedules are
fraught with imprecision, but the concurrent triplet combination
of carboplatin/paclitaxel/gemcitabine appears to produce signifi-
cant bone marrow suppression which may make this difficult to
deliver consistently in the nontrial setting (reviewed by Hansen,
2002).
Dyspnoea was markedly increased in both gemcitabine-contain-
ing arms; however, it was much more clinically significant in the
weekly docetaxel–gemcitabine arm, which was also associated
with pulmonary infiltration in three patients and one death due to
pulmonary toxicity. Lung toxicity has been reported with other
weekly taxane–gemcitabine schedules – for example, in the
SCOTROC 2C trial, where patients were treated with four cycles
of carboplatin followed by weekly paclitaxel–gemcitabine in
patients with ovarian cancer (Harries et al, 2004). One trial with
paclitaxel plus weekly gemcitabine was discontinued as four out of
12 patients with non-small-cell lung cancer experienced dose-
Table 2 Tumour responses after eight cycles of chemotherapy (by treatment arm)
Carboplatin followed by docetaxel
alone
(arm A) (n¼25)
Carboplatin followed by docetaxel–gemcitabine
(3-weekly) (arm B) (n¼22)
Carboplatin followed by
docetaxel–gemcitabine (weekly)
(arm C) (n¼23)
Response % Count % Count % Count
CR 40.0 10 45.5 10 30.4 7
PR 44.0 11 31.8 7 39.1 9
Stable 8.0 2 9.1 2 8.7 2
Progression 8.0 2 4.5 1 13.0 3
Unevaluable 0.0 0 9.1 2 8.7 2
CR¼complete response; PR¼partial response.
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slimiting pneumonitis (Thomas et al, 2000). While both docetaxel
and gemcitabine can be associated with pulmonary toxicities, it
was the weekly schedule that appeared to be associated with the
development of pulmonary toxicity in the present trial. Although
this regimen led to one fatality, this toxicity was otherwise
reversible (resolving with time and corticosteroid use). Further
evaluation of this toxicity should be undertaken, as it could impact
on protocol design for weekly combinations of these agents.
Sequential scheduling with a platinum agent followed by a
taxane – with or without other chemotherapeutic agents – has been
investigated in several early phase studies in ovarian cancer.
Unacceptable neurotoxicity with sequential cisplatin (100mgm
 2
for four cycles) and paclitaxel (200mgm
 2 for four cycles) has
been reported (Poole et al, 2000), although in most cases
sequential scheduling allowed planned dose intensity to be
achieved (Tognoni et al, 2000; Guppy et al, 2004). Importantly,
sequential scheduling did not incur loss of efficacy; in these
studies, median overall survival ranged from 22 to 30 months
(Poole et al, 2000; Tognoni et al, 2000; Guppy et al, 2004). In
SCOTROC 2C, the response rate in evaluable patients was 84%,
with a median progression-free survival of 19.5 months at a
median follow-up of 28 months (Harries et al, 2004). In our study,
the response rate of 66% after single-agent carboplatin was
improved following sequential treatment with docetaxel-based
regimens. Carboplatin followed by docetaxel alone (arm A)
produced the highest response rate (84%, compared with 77% in
arm B and 70% in arm C). However, carboplatin followed by 3-
weekly docetaxel–gemcitabine (arm B) was associated with the
best-observed survival outcome, with a median progression-free
survival time of 18.1 months (95% CI: 15.9–20.3) – compared with
15.5 months (95% CI: 10.5–20.6) for arm A and 13.7 months (95%
CI: 12.8–14.6) for arm C.
In conclusion, although just failing our formal feasibility
criteria, we believe that, all taken together, the observed data for
sequential chemotherapy with four cycles of carboplatin followed
by 3-weekly docetaxel-based therapy suggests that this is a realistic
option for first-line therapy of ovarian cancer. Preliminary results
of the SCOTROC 2B study, which investigated carboplatin followed
by docetaxel alone or 3-weekly docetaxel–irinotecan (Jayson et al,
2003), further support this sequential approach and suggest further
investigation in ovarian cancer is warranted. Following the results
of SCOTROC 2C (Harries et al, 2004), in which pulmonary toxicity
was noted with the weekly paclitaxel–gemcitabine schedule, a
further feasibility study with the 3-weekly paclitaxel–gemcitabine
schedule has also been initiated. We aim to analyse the results of
all the SCOTROC 2 trials together (including docetaxel and
paclitaxel-based schedules) in order to evaluate the optimal
sequence and drug combination for future Phase III testing of a
sequential approach to standard, concurrent two-drug chemo-
therapy administration.
ACKNOWLEDGEMENTS
This trial was funded by grants from Aventis Pharma and Eli Lilly
and Company, who also supplied Taxotere
s and Gemzar
s,
respectively.
Table 3 Haematological (grade 3–4) and nonhaematological (grade 2–4) toxicities (worst grade over cycles of docetaxel-based chemotherapy received)
Docetaxel alone
(arm A)
Docetaxel–gemcitabine
(3-weekly) (arm B)
Docetaxel–gemcitabine
(weekly) (arm C)
Toxicity Grade % Count % Count % Count
Haematological
Neutropenia 3 11.1 4 38.1 16 22.9 8
4 66.7 24 47.6 20 28.6 10
White blood cells 3 40.5 15 40.5 17 42.9 15
4 24.3 9 7.1 3 5.7 2
Platelets 3 8.1 3 4.8 2 11.4 4
4 0.0 0 4.8 2 0.0 0
Haemoglobin 3 0.0 0 9.5 4 8.6 3
4 0.0 0 2.4 1 2.9 1
Nonhaematological
Alopecia 2 73.0 27 64.3 27 19.8 7
Nausea 2 13.5 5 9.5 4 28.6 10
3 0.0 0 7.1 3 2.9 1
Vomiting 2 8.1 3 2.4 1 11.4 4
3 0.0 0 4.8 2 2.9 1
Sensory neuropathy 2 13.5 5 4.8 2 5.7 2
3 2.7 1 0.0 0 0.0 0
Motor neuropathy 2 2.7 1 0.0 0 0.0 0
3 0.0 0 2.4 1 2.9 1
Diarrhoea 2 16.2 6 11.9 5 14.3 5
3 2.7 1 7.1 3 0.0 0
Constipation 2 16.2 6 9.5 4 11.4 4
3 0.0 0 2.4 1 5.7 1
Stomatitis 2 29.7 11 21.4 9 2.9 1
3 5.4 2 0 0 0.0 0
Shortness of breath 2 10.8 4 35.7 15 40.0 14
3 0.0 0 4.8 2 5.7 2
4 0.0 0 0.0 0 2.9 1
Abdominal pain or cramping 2 10.8 4 4.8 2 8.6 3
3 0.0 0 2.4 1 5.7 2
4 0.0 0 2.4 1 0.0 0
Fatigue (lethargy, malaise, asthenia) 2 43.2 16 48.6 18 51.4 18
3 5.4 2 2.7 1 17.1 6
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